What do the trials say — and why is the thyroid finding both the best and the hardest evidence?
Ashwagandha's evidence base is small but unusually pharmacologic for a botanical: the cortisol-lowering is replicated across multiple trials, the GAD anxiety evidence is real but small (single-lineage concentration, the honest caveat), the thyroid trial is the field's most consequential and most double-edged finding (TSH normalization in subclinical hypothyroidism — with the case-report mirror), and the sleep, testosterone, and athletic-performance literatures are the promising-thin tier. This chapter reads the trials with the standardization discipline the molecule demands.
The botanical field with real pharmacology teaches formulation-aware reading:
Ayurveda's foundational text classifies ashwagandha among the premier Rasayana herbs — the rejuvenative class — establishing 2,400+ years of systematic use.
The steroidal lactone family is characterized — the active constituents isolated and the pharmacology begins to move from tradition to molecule.
The animal-model literature establishes the HPA-axis and thyroid mechanisms — the adaptogen concept gaining pharmacological legs.
The standardized extracts (KSM-66, Sensoril) launch the human-trial programs: the cortisol studies, the GAD trial, the subclinical-hypothyroidism trial — the evidence base this page grades.
The thyrotoxicosis case reports document the thyroid stimulation's clinical edge; the regulatory and safety literature catches up with the pharmacology's implications.
POPULATION · 64 adults with diagnosed GAD, KSM-66 600 mg daily vs. placebo, 8 weeks
FINDING · Significant anxiety-score reduction (55.77% vs. 30.52% response) and cortisol reduction in the treatment group — the anchor trial our anxiety page carries.
LIMITATION · Small sample, single center, industry affiliation (the KSM-66 manufacturer's trial) — the single-lineage concentration the reading lesson addresses. The effect is real but modestly powered.
POPULATION · 50 adults with elevated TSH and normal T4, KSM-66 600 mg daily, 8 weeks
FINDING · TSH normalized in a substantial fraction of the treatment group versus placebo — the dial demonstrably turned, the thyroid page's double-edge anchor.
LIMITATION · Very small, single center, industry-affiliated — and the same thyroid-stimulating activity underlies the thyrotoxicosis case reports. The physician supervision is part of the evidence, not a footnote.
POPULATION · Published case series of ashwagandha-associated thyroid hormone excess
FINDING · Documented cases of thyrotoxicosis in ashwagandha users with underlying thyroid susceptibility — resolution upon discontinuation, the mechanism matching the thyroid-stimulating pharmacology.
LIMITATION · Case reports (the rare-harm pattern our zinc page teaches); the causality is supported by the mechanism and the resolution pattern. The clinical translation: the thyroid workup precedes the adaptogen.
POPULATION · Adults with sleep complaints, standardized extract vs. placebo
FINDING · Improved sleep-quality scores and sleep latency — the somnifera name's modern support.
LIMITATION · Small trials, subjective endpoints, the insomnia-population question is different from general adult use. Our sleep page grades ashwagandha's evidence modestly.